Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by francois21on May 14, 2014 3:26pm
403 Views
Post# 22561924

Back from the AGM...

Back from the AGM...I will hold my shares to at least 2017..... 4050 is in healthy volunteers right now, no news, so no bad news. After phase Ib/II in 2015, a decision will have to be made regarding the application targeted. IPF can be granted as a fast track designation. However, the physical conditons of those patients can drasticly change within a few days, and a person can die anytime. This represent a risk in a clinical trial. The patient with CKD have a more stable and previsible health condition, which is better for monitoring the risk in a clinical trial.
Bullboard Posts